Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Centre Leon Berard
With
Ministry of Health, France
The secondary objectives are:
* Validation of the Lent-Soma toxicity scale by comparison to the RTOG scale,
* Response rate at different times: week 6-8, 1 year and 2 years after the end of irradiation,
* Progression-free survival rate at 1 year and 2 years after the end of irradiation
* Confirmation of the predictive value of serum cytokine levels (IL-6 and IL-10) during irradiation for the occurrence of early radiation toxicity, and analysis of the correlation between these serum levels at inclusion and the expression polymorphism of candidate genes.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Non-metastatic cytologically or histologically proven non-small-cell lung cancer (NSCLC)
Conformational thoracic radiotherapy with curative intent
Age \>= 18
Complete functional respiratory evaluation (FRE) performed less than 2 months before inclusion, demonstrating a maximum expiratory flow-volume/second \> 1 l (in case surgery, the FRE must have been realized in the post-surgery period)
Thoracic CT-scan performed less than 2 months before inclusion for non-operated patient
PET-scan performed less than 2 months before inclusion for non-operated patient
Performance status (PS) ECOG \<= 1
Possible training on breath holding technique
Female patients of childbearing potential: effective method of contraception necessary
Mandatory affiliation with a social security system
Written, signed, informed consent
You may not be if
Small-cell lung cancer
Metastatic disease
Infiltrating pulmonary disease
Previous thoracic irradiation
Indication of irradiation with palliative intent
Previous or concurrent primary malignancies at other sites (except basocellular skin cancer or cervical cancer in situ or complete remission for more than 5 years)